



Achillion Pharmaceuticals
Investor Relations Department
300 George St.
New Haven, CT 06511
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: ACHN

Last Trade: 2.83

Trade Time: 4:00 PM ET
Dec 12, 2017

Change: -0.03 ↓ (-1.049%)

Day Range: 2.80 - 2.91

52-Week Range: 2.85 - 5.66

Volume: 1,439,617

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile


Rooted in the myth of Achilles, the name of Achillion refers to the brave warrior committed to a cause as well as the company's mission to combat diseases by identifying and exploiting their unique vulnerabilities.

Inspiring Science. Innovative Medicine.

Achillion Pharmaceuticals, Inc. (Nasdaq: ACHN) is a science-driven, patient-focused company leveraging its strengths across the continuum from drug discovery to commercialization to provide better treatments for people with serious diseases.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

Nov 15, 2017

[Achillion Announces Pricing of Secondary Offering Of Common Stock](#)

Nov 14, 2017

[Achillion Announces Proposed Secondary Offering of Common Stock](#)

Nov 14, 2017

[Achillion Reports Preliminary Proof-of-Concept With ACH-4471 for the Treatment of C3G](#)

Nov 6, 2017

[Achillion Announces ACH-4471 Granted Orphan Drug Designation by the FDA and Positive Opinion for Orphan Drug Designation in the European Union for the Treatment of Paroxysmal Nocturnal Hemoglobinuria](#)

Nov 1, 2017

[Achillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical Programs](#)

Financial Disclosures [\[View all \]](#)

[Third Quarter Financial Results](#)

Feb 23, 2017

[Annual Report \(10-K\)](#)

Apr 17, 2017

[Proxy Statement \(DEF 14A\)](#)

Nov 1, 2017

[Quarterly Report \(10-Q\)](#)

Aug 8, 2017

[Quarterly Report \(10-Q\)](#)

May 4, 2017

[Quarterly Report \(10-Q\)](#)